The results corresponding to two multiple-choice questions are presented, one referring to initial therapy and one referring to add-on therapy prescribed for patients that remain symptomatic despite initial therapy. Some of the participants gave a duplicate answer, as they selected the same drug class in both questions (column ‘Participants that gave a duplicate answer’). The total number of physicians that reported prescribing each drug class for the therapy of DCM-related symptomatic heart failure is presented under column ‘overall total’.

Drugs reported under ‘other’ were acetylsalicylic acid and ivabradine for initial therapy and ivabradine and intravenous inotropics for add-on therapy.

ACE-I, angiotensin-converting enzyme inhibitors; DCM, dilated cardiomyopathy.